Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System

Stock Information for Adagio Medical Holdings Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adagio Medical Holdings Inc

Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors
Adagio Medical Reports Third Quarter 2025 Results
Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia
Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities
Adagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium
Adagio Medical, Inc. Announces Completion of Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Ventricular Tachycardia
Adagio Medical FULCRUM-VT U.S. Pivotal Study Acute Results to be Presented in Late-Breaking Session at VT Symposium

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.